South San Francisco, California, and San Diego witnessed an announcement from ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) on December 5, 2025. The clinical stage oncology firm, dedicated to creating treatments combating therapeutic resistance mechanisms, revealed the granting of 69,200 non-qualified stock options and 11,400 restricted stock units on December 1, 2025. These were awarded to three fresh non-executive employees hired by ORIC in November 2025.